The National Health Service (NHS) rollout of artificial pancreas technology—formally known as hybrid closed-loop systems—has shown early success in narrowing long-standing disparities in diabetes care. Data from the first two years of the program indicate that the gap in access to this transformative technology between patients from different socioeconomic and ethnic backgrounds has been significantly reduced, marking a notable shift in the delivery of diabetes treatment across England.
Historically, patients from minority ethnic backgrounds and those living in more deprived areas have faced systemic barriers to accessing advanced diabetes tools, such as continuous glucose monitors (CGMs). However, current figures reveal only a 3% difference in uptake between the most and least deprived populations, as well as between minority ethnic groups and their white counterparts. This progress suggests that the NHS rollout of artificial pancreas narrows inequality in diabetes care, providing a more uniform standard of support for those living with type 1 diabetes.
Understanding Hybrid Closed-Loop Systems
A hybrid closed-loop system functions as an automated bridge between a patient and their insulin needs. The technology integrates three distinct, interconnected components: a continuous glucose monitor worn on the body, an algorithm that calculates precise insulin requirements, and an insulin pump that delivers the necessary dosage directly into the bloodstream. By automating these calculations, the system alleviates the significant mental and physical burden of manual blood sugar management, particularly during sleep and mealtimes.
Clinical trials have consistently demonstrated that this technology offers superior glucose control compared to using CGMs alone. For many patients, the shift from traditional injections to an automated pump is not merely a technical upgrade; It’s a fundamental change in their quality of life. The device reduces the frequency of life-threatening complications, such as diabetic ketoacidosis, which can occur when insulin management becomes inconsistent or difficult to maintain.
Personal Impact and Lived Experience
For individuals like 27-year-old Naiha Shafiq from London, the technology has proved to be life-changing. Before being fitted with an artificial pancreas three years ago, Shafiq frequently required hospital treatment for diabetic ketoacidosis. Managing her condition with traditional injections presented additional challenges, particularly regarding her religious practice and her need for privacy.
“As a Muslim woman who wears hijab it was extremely difficult for me to be on injections as I would always look for somewhere private to inject most times, and if there was nowhere private to inject I would miss injections because I wasn’t comfortable. The pump makes life now so much easier,” Shafiq explained. Her experience underscores how medical technology, when distributed equitably, can address both the physiological and social barriers faced by patients.
Scaling the Program Across the UK
The NHS program, which began with a focus on children and young people, has already reached approximately 32,000 children—representing 72.3% of those eligible for the device. In 2023, the health service announced plans to expand this offer to more than 150,000 adults and children living with type 1 diabetes. This multi-year initiative aims to ensure that every eligible patient eventually has access to the technology, regardless of their background or geographic location.
Health officials and advocacy groups have lauded the progress while acknowledging that the work is far from complete. Helen Kirrane, head of policy and campaigns at Diabetes UK, emphasized the importance of the program’s focus on equity. “We’re incredibly proud of the role Diabetes UK research and advocacy has played in getting us to this point, where a world-leading rollout is taking place on the NHS with equity at its very core,” Kirrane said. She added that the challenge remains to ensure the technology reaches every eligible person across the UK.
Hilary Nathan, director of policy at Breakthrough T1D, echoed these sentiments, noting that the UK is currently positioned as a global leader in the implementation of these systems. “The priority now is to ensure equitable access across all four nations of the UK, so that everyone has a genuine choice of the technology that suits them when they need it,” Nathan stated.
Clinical Leadership and Future Steps
Dr. Clare Hambling, the National Clinical Director for diabetes and obesity, credited the success of the initiative to the dedicated efforts of paediatric diabetes teams nationwide. By prioritizing the most vulnerable and ensuring rapid access, these teams have transformed the standard of care for thousands of families. The progress seen in these first two years serves as a benchmark for the next phase of the rollout, which will continue to integrate more adults into the program.
While the initial data on reducing inequality are promising, maintaining this momentum will require sustained clinical support and consistent funding. The program is designed to continue over the next few years, with the ultimate goal of providing full coverage for all eligible patients with type 1 diabetes.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or diabetes management technology.
As the rollout continues, the NHS is expected to provide periodic updates on the expansion of eligibility and access metrics. Patients interested in learning more about their eligibility for hybrid closed-loop systems should consult their local diabetes care team or visit the official NHS website for the latest guidance.
We invite our readers to share their thoughts or experiences with diabetes technology in the comments section below.
